HOTH vs. DRRX, ANVS, JATT, NKGN, RNXT, PMN, LEXX, CDIO, ENLV, and BIVI
Should you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include DURECT (DRRX), Annovis Bio (ANVS), JATT Acquisition (JATT), NKGen Biotech (NKGN), RenovoRx (RNXT), ProMIS Neurosciences (PMN), Lexaria Bioscience (LEXX), Cardio Diagnostics (CDIO), Enlivex Therapeutics (ENLV), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry.
Hoth Therapeutics vs.
Hoth Therapeutics (NASDAQ:HOTH) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Hoth Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 253.98%. DURECT has a consensus price target of $5.00, indicating a potential upside of 510.95%. Given DURECT's higher probable upside, analysts plainly believe DURECT is more favorable than Hoth Therapeutics.
In the previous week, Hoth Therapeutics had 10 more articles in the media than DURECT. MarketBeat recorded 12 mentions for Hoth Therapeutics and 2 mentions for DURECT. Hoth Therapeutics' average media sentiment score of 0.08 beat DURECT's score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the media.
7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 10.6% of Hoth Therapeutics shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Hoth Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
DURECT received 240 more outperform votes than Hoth Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Hoth Therapeutics an outperform vote while only 62.08% of users gave DURECT an outperform vote.
Hoth Therapeutics has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks.
Hoth Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Hoth Therapeutics' return on equity of -89.68% beat DURECT's return on equity.
Summary
Hoth Therapeutics beats DURECT on 11 of the 18 factors compared between the two stocks.
Get Hoth Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hoth Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HOTH) was last updated on 3/12/2025 by MarketBeat.com Staff
